作者
Ganesh Raghu, Juergen Behr, Kevin K Brown, Jim J Egan, Steven M Kawut, Kevin R Flaherty, Fernando J Martinez, Steven D Nathan, Athol U Wells, Harold R Collard, Ulrich Costabel, Luca Richeldi, Joao De Andrade, Nasreen Khalil, Lake D Morrison, David J Lederer, Lixin Shao, Xiaoming Li, Patty S Pedersen, A Bruce Montgomery, Jason W Chien, Thomas G O'Riordan, ARTEMIS-IPF Investigators*
发表日期
2013/5/7
期刊
Annals of internal medicine
卷号
158
期号
9
页码范围
641-649
出版商
American College of Physicians
简介
Chinese translation
This article has been corrected. The original version (PDF) is appended to this article as a Supplement.
Background
Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.
Objective
To determine whether ambrisentan, an ETA receptor–selective antagonist, reduces the rate of IPF progression.
Design
Randomized, double-blind, placebo-controlled, event-driven trial. (ClinicalTrials.gov: NCT00768300)
Setting
Academic and private hospitals.
Participants
Patients with IPF aged 40 to 80 years with minimal or no honeycombing on high-resolution …
学术搜索中的文章
G Raghu, J Behr, KK Brown, JJ Egan, SM Kawut… - Annals of internal medicine, 2013